MXPA04011835A - Tratamiento de combinacion para la depresion y ansiedad. - Google Patents
Tratamiento de combinacion para la depresion y ansiedad.Info
- Publication number
- MXPA04011835A MXPA04011835A MXPA04011835A MXPA04011835A MXPA04011835A MX PA04011835 A MXPA04011835 A MX PA04011835A MX PA04011835 A MXPA04011835 A MX PA04011835A MX PA04011835 A MXPA04011835 A MX PA04011835A MX PA04011835 A MXPA04011835 A MX PA04011835A
- Authority
- MX
- Mexico
- Prior art keywords
- pde
- antidepressant
- inhibitor
- anxiety
- combination
- Prior art date
Links
- 230000001430 anti-depressive effect Effects 0.000 title abstract 3
- 239000000935 antidepressant agent Substances 0.000 title abstract 3
- 229940005513 antidepressants Drugs 0.000 title abstract 3
- 239000002249 anxiolytic agent Substances 0.000 title abstract 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract 3
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion se refiere a un metodo para tratar la depresion o la ansiedad en un mamifero, incluido un ser humano, al administrar al mamifero un inhibidor de PDE IV en combinacion con un agente antidepresivo o un agente ansiolitico; tambien se refiere a composiciones farmaceuticas que contienen un vehiculo farmaceuticamente aceptable, un inhibidor de PDE IV y un agente ansiolitico o antidepresivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38918102P | 2002-06-17 | 2002-06-17 | |
PCT/IB2003/002295 WO2003105902A1 (en) | 2002-06-17 | 2003-06-05 | Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04011835A true MXPA04011835A (es) | 2005-03-31 |
Family
ID=29736598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04011835A MXPA04011835A (es) | 2002-06-17 | 2003-06-05 | Tratamiento de combinacion para la depresion y ansiedad. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20030235631A1 (es) |
EP (1) | EP1517707A1 (es) |
JP (1) | JP2005533788A (es) |
AU (1) | AU2003233032A1 (es) |
BR (1) | BR0311903A (es) |
CA (1) | CA2488138A1 (es) |
MX (1) | MXPA04011835A (es) |
WO (1) | WO2003105902A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US7071333B2 (en) | 2003-07-30 | 2006-07-04 | Bristol-Myers Squibb Company | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
US20050154006A1 (en) * | 2004-01-09 | 2005-07-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives |
DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
DE102004046236A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
US20070105878A1 (en) * | 2005-10-03 | 2007-05-10 | Andrew Reaume | Purine formulations and methods for managing disorders |
US20070213370A1 (en) * | 2005-11-18 | 2007-09-13 | H. Lundbeck A/S | 5-HTP Combination Therapy |
US20070117844A1 (en) * | 2005-11-18 | 2007-05-24 | Morillo Connie S | 5-HTP combination therapy |
US20100056791A1 (en) * | 2006-09-01 | 2010-03-04 | Yasushi Kohno | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
US8198268B2 (en) * | 2008-10-31 | 2012-06-12 | Janssen Biotech, Inc. | Tianeptine sulfate salt forms and methods of making and using the same |
US8202525B2 (en) * | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
CN107875152B (zh) * | 2015-12-17 | 2020-03-24 | 浙江工业大学 | 含氮杂环类化合物在制备单胺氧化酶抑制剂中的应用 |
WO2023109802A1 (zh) * | 2021-12-14 | 2023-06-22 | 海思科医药集团股份有限公司 | 三环稠杂环类pde3/4双重抑制及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030022814A1 (en) * | 2000-02-29 | 2003-01-30 | Reines Scott A | Method for treating or preventing depression |
US20030069169A1 (en) * | 2001-03-02 | 2003-04-10 | Macor John E. | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
-
2003
- 2003-03-12 US US10/387,060 patent/US20030235631A1/en not_active Abandoned
- 2003-06-05 WO PCT/IB2003/002295 patent/WO2003105902A1/en not_active Application Discontinuation
- 2003-06-05 JP JP2004512802A patent/JP2005533788A/ja active Pending
- 2003-06-05 CA CA002488138A patent/CA2488138A1/en not_active Abandoned
- 2003-06-05 EP EP03727833A patent/EP1517707A1/en not_active Withdrawn
- 2003-06-05 MX MXPA04011835A patent/MXPA04011835A/es unknown
- 2003-06-05 BR BR0311903-3A patent/BR0311903A/pt not_active IP Right Cessation
- 2003-06-05 AU AU2003233032A patent/AU2003233032A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2488138A1 (en) | 2003-12-24 |
US20030235631A1 (en) | 2003-12-25 |
AU2003233032A1 (en) | 2003-12-31 |
WO2003105902A1 (en) | 2003-12-24 |
BR0311903A (pt) | 2005-06-07 |
EP1517707A1 (en) | 2005-03-30 |
JP2005533788A (ja) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP034922A (es) | Pirrolopirimidinas | |
MXPA04011835A (es) | Tratamiento de combinacion para la depresion y ansiedad. | |
HK1057899A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
ZA200706029B (en) | Tricyclic &-opioid domulators | |
IL181700A0 (en) | Quinazoline derivatives and pharmaceutical compositions containing the same | |
TW200606162A (en) | Pyrazolopyridine derivatives | |
HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
MY140840A (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
MY148647A (en) | Pharmaceutical compositions comprising a camtothecin derivative | |
GB0002336D0 (en) | Medicaments | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
EP1213031A3 (en) | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | |
EP1254668A3 (en) | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression | |
EP1262196A3 (en) | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence | |
MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
SG153661A1 (en) | Formulation and methods for the treatment of thrombocythemia | |
EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
GB2446341A (en) | Method and system for transdermal drug delivery | |
MX2007005525A (es) | Tratamiento terapeutico de resorcion ose acelerada. | |
MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors |